Mette L Johansen1,2,3, L C Stetson4,2, Vachan Vadmal2,3, Kristin Waite3,5, Michael E Berens6, James R Connor7, Justin Lathia2,8, Joshua B Rubin9, Jill S Barnholtz-Sloan2,3,5. 1. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 2. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 3. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 4. Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 5. Cleveland Center for Health Outcomes Research, Cleveland, Ohio, USA. 6. Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona, USA. 7. Department of Neurosurgery, Penn State College of Medicine, Hershey, Pennsylvania, USA. 8. Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. 9. Departments of Pediatrics and Neuroscience, Washington University School of Medicine, St. Louis, Missouri, USA.
Abstract
BACKGROUND: Gliomas are the most common type of primary brain tumor and one of many cancers where males are diagnosed with greater frequency than females. However, little is known about the sex-based molecular differences in glioblastomas (GBMs) or lower grade glioma (non-GBM) subtypes. DNA methylation is an epigenetic mechanism involved in regulating gene transcription. In glioma and other cancers, hypermethylation of specific gene promoters downregulates transcription and may have a profound effect on patient outcome. The purpose of this study was to determine if sex-based methylation differences exist in different glioma subtypes. METHODS: Molecular and clinical data from glioma patients were obtained from The Cancer Genome Atlas and grouped according to tumor grade and molecular subtype (IDH1/2 mutation and 1p/19q chromosomal deletion). Sex-specific differentially methylated probes (DMPs) were identified in each subtype and further analyzed to determine if they were part of differentially methylated regions (DMRs) or associated with differentially methylated DNA transcription regulatory binding motifs. RESULTS: Analysis of methylation data in 4 glioma subtypes revealed unique sets of both sex-specific DMPs and DMRs in each subtype. Motif analysis based on DMP position also identified distinct sex-based sets of DNA-binding motifs that varied according to glioma subtype. Downstream targets of 2 of the GBM-specific transcription binding sites, NFAT5 and KLF6, showed differential gene expression consistent with increased methylation mediating downregulation. CONCLUSION: DNA methylation differences between males and females in 4 glioma molecular subtypes suggest an important, sex-specific role for DNA methylation in epigenetic regulation of gliomagenesis.
BACKGROUND: Gliomas are the most common type of primary brain tumor and one of many cancers where males are diagnosed with greater frequency than females. However, little is known about the sex-based molecular differences in glioblastomas (GBMs) or lower grade glioma (non-GBM) subtypes. DNA methylation is an epigenetic mechanism involved in regulating gene transcription. In glioma and other cancers, hypermethylation of specific gene promoters downregulates transcription and may have a profound effect on patient outcome. The purpose of this study was to determine if sex-based methylation differences exist in different glioma subtypes. METHODS: Molecular and clinical data from glioma patients were obtained from The Cancer Genome Atlas and grouped according to tumor grade and molecular subtype (IDH1/2 mutation and 1p/19q chromosomal deletion). Sex-specific differentially methylated probes (DMPs) were identified in each subtype and further analyzed to determine if they were part of differentially methylated regions (DMRs) or associated with differentially methylated DNA transcription regulatory binding motifs. RESULTS: Analysis of methylation data in 4 glioma subtypes revealed unique sets of both sex-specific DMPs and DMRs in each subtype. Motif analysis based on DMP position also identified distinct sex-based sets of DNA-binding motifs that varied according to glioma subtype. Downstream targets of 2 of the GBM-specific transcription binding sites, NFAT5 and KLF6, showed differential gene expression consistent with increased methylation mediating downregulation. CONCLUSION: DNA methylation differences between males and females in 4 glioma molecular subtypes suggest an important, sex-specific role for DNA methylation in epigenetic regulation of gliomagenesis.
Authors: Wei Yang; Nicole M Warrington; Sara J Taylor; Paula Whitmire; Eduardo Carrasco; Kyle W Singleton; Ningying Wu; Justin D Lathia; Michael E Berens; Albert H Kim; Jill S Barnholtz-Sloan; Kristin R Swanson; Jingqin Luo; Joshua B Rubin Journal: Sci Transl Med Date: 2019-01-02 Impact factor: 17.956
Authors: Min-Hee Yi; Young Sook Lee; Joon Won Kang; Soo Jin Kim; Sang-Ha Oh; Yong Min Kim; Young Ho Lee; Sang Do Lee; Dong Woon Kim Journal: Cell Mol Neurobiol Date: 2012-11-20 Impact factor: 5.046
Authors: Yuan Tian; Tiffany J Morris; Amy P Webster; Zhen Yang; Stephan Beck; Andrew Feber; Andrew E Teschendorff Journal: Bioinformatics Date: 2017-12-15 Impact factor: 6.937
Authors: Camila Ferreira de Souza; Thais S Sabedot; Tathiane M Malta; Lindsay Stetson; Olena Morozova; Artem Sokolov; Peter W Laird; Maciej Wiznerowicz; Antonio Iavarone; James Snyder; Ana deCarvalho; Zachary Sanborn; Kerrie L McDonald; William A Friedman; Daniela Tirapelli; Laila Poisson; Tom Mikkelsen; Carlos G Carlotti; Steven Kalkanis; Jean Zenklusen; Sofie R Salama; Jill S Barnholtz-Sloan; Houtan Noushmehr Journal: Cell Rep Date: 2018-04-10 Impact factor: 9.423
Authors: Pablo Monterroso; Kristin J Moore; Jeannette M Sample; Natali Sorajja; Allison Domingues; Lindsay A Williams Journal: Cancer Epidemiol Date: 2021-12-09 Impact factor: 2.984
Authors: Cesar A Garcia; Adip G Bhargav; Mieu Brooks; Paola Suárez-Meade; Sujan K Mondal; Natanael Zarco; Karim ReFaey; Mark Jentoft; Erik H Middlebrooks; Matija Snuderl; Anna Carrano; Hugo Guerrero-Cazares; Paula Schiapparelli; Rachel Sarabia-Estrada; Alfredo Quiñones-Hinojosa Journal: Mol Cancer Ther Date: 2021-08-31 Impact factor: 6.009
Authors: Gi-Ming Wang; Gino Cioffi; Nirav Patil; Kristin A Waite; Robert Lanese; Quinn T Ostrom; Carol Kruchko; Michael E Berens; James R Connor; Justin D Lathia; Joshua B Rubin; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2022-02-01 Impact factor: 13.029
Authors: Guangze Zhao; Sana Aghakeshmiri; Yankuan T Chen; Huifang M Zhang; Fione Yip; Decheng Yang Journal: Int J Mol Sci Date: 2021-05-04 Impact factor: 5.923